CN102309001B - Food composition and pharmaceutical composition of lactic acid bacteria strains for treating allergies - Google Patents
Food composition and pharmaceutical composition of lactic acid bacteria strains for treating allergies Download PDFInfo
- Publication number
- CN102309001B CN102309001B CN2010102267377A CN201010226737A CN102309001B CN 102309001 B CN102309001 B CN 102309001B CN 2010102267377 A CN2010102267377 A CN 2010102267377A CN 201010226737 A CN201010226737 A CN 201010226737A CN 102309001 B CN102309001 B CN 102309001B
- Authority
- CN
- China
- Prior art keywords
- cell
- acid bacteria
- antianaphylaxis
- milk
- bacterial strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract description 94
- 235000014655 lactic acid Nutrition 0.000 title abstract description 47
- 239000004310 lactic acid Substances 0.000 title abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 title abstract description 4
- 230000007815 allergy Effects 0.000 title abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 claims description 39
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 31
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 13
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000028993 immune response Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 49
- 102100037850 Interferon gamma Human genes 0.000 description 26
- 108010074328 Interferon-gamma Proteins 0.000 description 26
- 229960003130 interferon gamma Drugs 0.000 description 22
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 108010065805 Interleukin-12 Proteins 0.000 description 16
- 102000013462 Interleukin-12 Human genes 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 244000199866 Lactobacillus casei Species 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 13
- 229940117681 interleukin-12 Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 235000013958 Lactobacillus casei Nutrition 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 229940017800 lactobacillus casei Drugs 0.000 description 10
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 10
- 210000004989 spleen cell Anatomy 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000000941 bile Anatomy 0.000 description 9
- 229940099352 cholate Drugs 0.000 description 9
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000002804 anti-anaphylactic effect Effects 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 230000001885 phytohemagglutinin Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000008821 health effect Effects 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000226932 Bifidobacterium bifidum BGN4 Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to novel strains of lactic acid bacteria and novel compositions containing such strains, which have not been known in the past, for enhancing their anti-allergic capabilities, which compositions may be in the form of food or pharmaceutical compositions. Also described are methods for screening and assaying the lactic acid bacteria composition to enhance the Th1 type immunity and thereby regulate the Th2 type immune response which is hyperreactive due to allergy.
Description
Technical field
The present invention is relevant a kind of food compositions and medical composition, particularly a kind of food compositions and medical composition that comprises antianaphylactic lactic bacterium strains.
Background technology
The general edible product that contains milk-acid bacteria (LAB) only has the health effect of adjusting enteron aisle, although there is ten hundreds of lactic bacterium strains to be present in nature, only has the minority lactobacillus strain to have antianaphylactic speciality.The ability of the acidproof and bile tolerance ability that these bacterial strains of minority have, absorption mucous membrane epidermic cell and the characteristics such as ability that still can survive after by intestines and stomach are the important evidence of screening when the bacterial strain of promotion health effect is arranged.Even to this day, only there is the verified lactic bacterium strains that it has the antianaphylaxis health effect of several strains to be identified out, and milk-acid bacteria is the specificity of bacterial strain (strain) but not bacterial classification (species) to healthy function, and this kind has the bacterial strain of special efficacy to be called functional probiotic bacterium (Guidelines for the evaluation of probiotics in food for the healthy of people; Report of j oint FAO/WHOworking group on drafting guidelines for the evaluation of probiotics in food; London Ontario, Canada April 30and May 1,2002:1-7).
Many milk-acid bacterias reported in literature relevant with anaphylaxis arranged both at home and abroad.Carry out aspect the zooperal research lowering irritated ability for milk-acid bacteria, the animal experiment that the dead milk-acid bacteria L.plantarum L-137 of thermic does can induce the scavenger cell of DBA/2 mouse and spleen cell to produce IL-12 and IFN-γ, and can suppress to have had the narrow spectrum IgE of casein (casein), increase is to the narrow spectrum IgG1 antibody of casein (Murosaki, 1998).Around OVA-TCR-Tg mouse feeding L.casei Shirota, increase spleen cell secretion of gamma-IFN and IL-12, reduce secretion IL-4 and IL-5 (Shida et al., 2002).OVA sensitization BALB/c mouse feeding milk-acid bacteria Lactobacillus fermented milk 27 days can reduce and has the OVA specific IgE in the serum (Ishida et al., 2003).The C3H/Hej mouse is through OVA and Toxins,exo-, cholera (cholera toxin) sensitization, feeding B.bifidum BGN4, L.casei 911, can make tool OVA specific IgE in the serum, IgA and total IgE, IgG1 reduce (Kim et al., 2005), these documents confirm on the animal experiment of irritated pattern, the feeding milk-acid bacteria can reduce the content of IgE in the serum, improves by this irritated situation.
Milk-acid bacteria is in clinical experiment, patient with anaphylactic disease can improve anaphylaxis really, merge and take dry milk-acid bacteria L.rhamnosus and six weeks of L.reuteri, helpful to anaphylactic disease, assess probiotic bacterium to one to 13 years old children's atopic dermatitis with the survey head of a family, find that children's atopic dermatitis of 56% is improved (Rosenfeldt et al., 2003).Ishida (2005) scholar drinks L.acidophilus strain L-92 for 49 Allergic Rhinitis, finds that also allergic symptom is improved.Take L.fermentum VRI eight weeks of 003 PCCTM, 53 children with atopic dermatitis symptom can increase PBMC cell generation IFN-γ, and improve irritated situation (Prescott et al., 2005).
(2006) etc. scholar's research points out to have the test that the atopic dermatitis patient does for 54, take L.rhamnosus strain GG and placebo after, can effectively improve allergic symptom.
Research points out that lactic-acid bacteria cells wall composition has immunoregulation capability, comprises Peptidoglycans (PG), Lipoteichoic acids (LTA), Phosphopolysaccharide.For example the Phosphopolysaccharide in the L.lactis cell walls can stimulate the mouse white cell to produce IFN-γ, and Teichoic acid and Muramyl dipeptide increase stimulates PBMC to produce IFN-γ (Cross et al., 2001); L.paracasei KW3110 cell wall constituent LTA can affect NF-κ B signal pipeline, has very strong immunoregulation ability (Fujiwara et al., 2004).
Probiotic strain has good efficacy for human body, and has many possible mechanisms to be suggested to illustrate why probiotic strain has desirable influence to human body.These mechanism mostly concentrate on improves the immunity system that intestinal mucosa cell function of shielding directly affects human body, the balance between the secretion of inflammatory cells hormone before for example suppressing, the activity that affects adjustment type T cell and the adjustment Th1/Th2.Improving the bacterium of adjusting the intestines and stomach fungal component period the infant is very important mutually, and infant's enteron aisle of many allergy lacks the probiotic bacterium flora, and Intestinal flora all has more aerogenesis folder film clostridium and less bifidus flora.Therefore there is enteron aisle in the probiotic bacterium clump, for the immunological competence construction of human body and to possess sound immunoregulation ability be very important key.Yet, the mechanism that affects human body for probiotic bacterium still not yet is finalized, for this point, in the development in future, still need more external and in vivo test to go explanation, the mechanism that human body is had a so good impact why and research be applied to optimal conditions on the human body (Michael et al., 2008).
Summary of the invention
Comprising by following any biological culture of one aspect of the present invention broad sense: lactobacillus reuteri (Lactobacillus reuteri) GL-104 bacterial strain, Chinese Typical Representative culture collection center preserving number M209138 bacterial strain, and physiologically acceptable the vehicle food compositions or the medical composition that form.
In another specific embodiment, the biological culture that comprises the of the same race or mutant of physiologically acceptable following any bacterial strain that strengthens the antianaphylaxis ability: lactobacillus reuteri (Lactobacillus reuteri) GL-104 bacterial strain, Chinese Typical Representative culture collection center preserving number M 209138.
Again, in another specific embodiment, but comprising via promoting cell IL-12 (IL-12) or interferon-gamma (IFN-gamma) to regulate and control Th1 type immune response and Immunosuppression sphaeroprotein IgE of the present invention's broad sense, improve the excessive immunoreactive allergic phenomena of Th2 type, it is that Mammals is given to reach any the aforementioned biological culture that stimulates Th1 type immune effect dosage.
But the present invention is comprising in the application's case specification sheets separately or part, constitutive requirements and the feature of sum total explanation of broad sense also, reach any any or all of combination any or multiple in these parts, constitutive requirements and the feature that comprises, if and described herein and clear and definite complete things when known coordinator in the related art techniques relevant with the present invention, having occurred, these known coordinators will be incorporated herein as independent item.
Description of drawings
Fig. 1 shows, when respectively with 10
6To 10
8The lactobacillus reuteri GL-104 bacterial strain M 209138 and 10 of cfu
5To 10
7Individual mouse spleen cell (Splenocyte) co-cultivation 48 hours is collected cell conditioned medium liquid, with the content of enzyme-linked immunosorbent assay detecting interferon-gamma (IFN-gamma) in supernatant liquor.Wherein take without antianaphylaxis function milk-acid bacteria (Lactobacillus casei BCRC17001) and Experimental Background value (Cell only) as negative control group, prove its milk-acid bacteria that antianaphylaxis effect is arranged (Lactobacillusrhamnosus GG BCRC 16000) and PHA as the positive control group to deliver most literature, detecting interferon-gamma irriate concentration.The result shows that test group can stimulate significantly mouse spleen cell (Splenocyte) secretion interferon-gamma and negative control group (Lactobacillus casei BCRC17001) that significant difference is arranged and exceeds nearly 4 times than the quantity of stimulus of positive control group (Lactobacillusrhamnosus GG BCRC 16000).
Fig. 2 shows, when respectively with 10
6To 10
8The lactobacillus reuteri GL-104 bacterial strain M 209138 and 10 of cfu
5To 10
7Individual human peripheral blood mononuclear cell (PBMC) co-cultivation 48 hours is collected cell conditioned medium liquid, with the content of enzyme-linked immunosorbent assay detecting interferon-gamma (IFN-gamma) in supernatant liquor.Wherein take without antianaphylaxis function milk-acid bacteria (Lactobacillus casei BCRC17001) and Experimental Background value (Cell only) as negative control group, prove its milk-acid bacteria that antianaphylaxis effect is arranged (Lactobacillusrhamnosus GG BCRC 16000) and PHA as the positive control group to deliver most literature, detecting interferon-gamma irriate concentration.The result shows that stimulating human peripheral blood mononuclear cell (PBMC) secretion interferon-gamma and negative control group (Lactobacillus casei BCRC17001) have significant difference and exceed 2.2 times than the quantity of stimulus of positive control group (Lactobacillus rhamnosus GG BCRC 16000) test group significantly.
Fig. 3 shows, when respectively with thermic dead 10
6To 10
8The lactobacillus reuteri GL-104 bacterial strain M 209138 and 10 of cfu
5To 10
7Individual human dcs (dendritic cell) co-cultivation 48 hours is collected cell conditioned medium liquid, with the content of enzyme-linked immunosorbent assay detecting cell interleukin 12 p40 in supernatant liquor.Wherein take without antianaphylaxis function milk-acid bacteria (Lactobacillus casei BCRC17001) and Experimental Background value (Cell only) as negative control group, prove its milk-acid bacteria that antianaphylaxis effect is arranged (Lactobacillus rhamnosus GG BCRC 16000) and LPS as the positive control group to deliver most literature, detecting cell interleukin 12 p40 (IL-12p40) irriate concentration.The result show test group significantly stimulating human dendritic cell secretory cell interleukin 12 p40 (IL-12p40) and negative control group (Lactobacillus casei BCRC17001) significant difference is arranged, and exceed 2 times than the quantity of stimulus of positive control group (Lactobacillus rhamnosus GG BCRC 16000).
Fig. 4 shows, lactobacillus reuteri GL-104 bacterial strain M 209138 is after the activation of substratum, total count is via simulation hydrochloric acid in gastric juice solution and cholate solution-treated different time, the bacterium number of lactobacillus reuteri GL-104 bacterial strain M 209138 is not affected by hydrochloric acid in gastric juice and cholate and sharply descends, and proves that antianaphylaxis lactic bacterium strains of the present invention can be by the test of the strict environment of digestion.
Fig. 5 shows, according to the analytical procedure of the scholars such as Jacobsen (1999), when the average bacterium number in each visual field is less than 40, is judged to be non-cohesive (nonadhesive); When the average bacterium number in each visual field between 41 to 100 the time, be judged to be and adhere to (adhesive); When the average bacterium number in each visual field greater than 100 the time, be judged to be strong adhesion (strongly adhesive).Show that lactobacillus reuteri GL-104 bacterial strain M 209138 is judged to be " strong adhesion ".
Embodiment
One aspect of the present invention broad sense comprise following biological culture: lactobacillus reuteri (Lactobacillus reuteri) GL-104 bacterial strain, Chinese Typical Representative culture collection center preserving number M 209138, and physiologically acceptable vehicle or the thinner food compositions or the medical composition that form.
Many documents are pointed out to increase the secretion increase that the first type T cell hormone comprises cell interleukin (IL-12), interferon-gamma (IFN-gamma), can effectively improve allergic symptom; Further class tongued bell acceptor (Toll-like receptor) combination on specific lactobacillus strain and the dendritic cell is also pointed out in research, the albumen of translating in the active cells moves in the nuclear and discharges a large amount of cytohormones, a ring that belongs to congenital immunity, therefore some specific lactic bacterium strains is by its cell wall polysaccharides class material such as peptidoglycan (peptidoglycan), saccharan (polysaccharide) etc., through innate immune system, really can activate the growth of T cell in the body.
The lyophilize culture of bacterial strain of the present invention has been deposited in Chinese Typical Representative culture collection center, and the address is China, Wuhan, Wuhan University 430072.The detail file of preservation are as shown in table 1:
Table 1
| The bacterial strain name | Numbering | Date |
| Lactobacillus reuteri GL-104 | M 209138 | On 08 14th, 2009 |
Found to have antianaphylactic ability such as this strains of lactic acid bacteria of the listed preservation of table 1, comprised that the symptom for atopic dermatitis, urticaria, allergic rhinitis, food anaphylaxis and asthma has the function of slowing down and treating.
Embodiment 1: the morphology of antianaphylaxis milk-acid bacteria and general aspects.
Confirm the feature of bacterial strain on taxonomy according to 16S rDNA sequential analysis and API Bacteria Identification systems analysis result.Find that Feng Hua strain number GL-104 is lactobacillus reuteri.The feature of this bacterial strain on morphology and general aspects listed in table 2 in detail:
Table 2
| The bacterial strain name | Morphological specificity |
| Lactobacillus reuteri GL-104 | 1. when the MRS nutrient solution was cultivated, thalline was rod-short, and two ends are rounded, usually separately appearance, paired or one-tenth short chain shape.2. the Gram-positive bacillus does not generate spore, does not have catalase, oxydase and a mobility, all can grow at aerobic and anaerobic environment, and optimum growth temperature is 37 ± 1 ℃, belongs to facultative heterogeneous fermentable bacterial strain, does not produce gas during glucose metabolism. |
Embodiment 2: the antianaphylaxis milk-acid bacteria is to the effect of the Secretion regulation Th1 type immunological competence of promotion interferon-gamma.
Inspect this strain antianaphylaxis lactobacillus strain, the enhancement effect of 209138 pairs of Th1 types of lactobacillus reuteri GL-104 bacterial strain M immunological competence, it is to measure mouse spleen cell (Splenocyte) and human peripheral blood mononuclearcell (Peripheral blood mononuclear cell, PBMC) measure respectively the secretory volume of interferon-gamma after co-cultivation with aforementioned this strain antianaphylaxis milk-acid bacteria, verify the bacterial strain with antianaphylaxis ability.Use following experimental procedure:
1. get the each about spleen of suitable mouse spleen and human blood amount and 200mL whole blood.
2. after spleen being put into buffered soln and smashing, centrifugal 5 minutes of 100g, it is for subsequent use to get supernatant liquor.
3. the blood cell parting liquid (Ficoll-paque) of getting equal proportion and spleen cell supernatant liquor and blood at 18-20 ℃ with the centrifugal 30-40 of 400g minute.
4. get spleen cell layer and human peripheral blood leukocyte cell layer, after buffered soln cleans cell 2-3 time, with suitable substratum (for example RPMI-1640) suspension cell.
With cell with activated 3 days lactobacillus strain with 1: 10 ratio co-cultivation 48 hours.
6. collect the supernatant liquor of cell cultures.Utilize the content of enzyme-linked immunosorbent assay (ELISA) detecting interferon-gamma (IFN-gamma) in supernatant liquor.
The statistical study of data such as table 3, table 4 and Fig. 1, shown in Figure 2 represent with Mean ± SD.Figure 1 and Figure 2 is ought be respectively with 10
6To 10
8Cfu lactobacillus reuteri GL-104 bacterial strain M 209138 and 10
5To 10
7Individual spleen cell and human peripheral blood mononuclearcell (PBMC) difference co-cultivation 48 hours are collected cell conditioned medium liquid, with the content of enzyme-linked immunosorbent assay detecting interferon-gamma (IFN-gamma) in supernatant liquor.Wherein take without antianaphylaxis function milk-acid bacteria (Lactobacillus casei BCRC 17001) and Experimental Background value (Cell only) as negative control group, prove its milk-acid bacteria that antianaphylaxis effect is arranged (Lactobacillus rhamnosus GG B CRC 16000) and PHA (Phytohemagglutinin) as the positive control group to deliver most literature, detecting interferon-gamma irriate concentration.The result shows that test group can stimulate significantly mouse spleen cell (Splenocyte) and human peripheral blood mononuclearcell (PBMC) secretion interferon-gamma and negative control group (Lactobacillus casei BCRC 17001) that significant difference is arranged and exceeds nearly 4 times (Splenocyte) and nearly 2.2 times (PBMC) than the quantity of stimulus of positive control group (Lactobacillusrhamnosus GG BCRC 16000).Table 3 and table 4 are that this strain antianaphylaxis bacterial strain and control group are cultivated with mouse spleen cell and human peripheral blood mononuclearcell (PBMC) respectively, stimulate the secretory volume (means+SD) of interferon-gamma:
Table 3Splenocyte
Table 4PBMC
| Strain name | The secretory volume of interferon-gamma (pg/mL) |
| Positive control group (L.rhamnosus GG BCRC 16000) | 8201±322 |
| Lactobacillus reuteri GL-104M 209138 | 15826±549 |
| Negative control group (L.casei BCRC17001) | 533±153 |
| Positive control group (PHA) | 14560±1084 |
| Negative control group (Cell only) | 46±30 |
Embodiment 3: the antianaphylaxis milk-acid bacteria is to the effect (take dendritic cell dendritic cell as external effect verification platform) of the Secretion regulation Th1 type immunological competence of promotion cell interleukin 12 p40 (IL-12p40).
Inspect antianaphylaxis lactic bacterium strains of the present invention-lactobacillus reuteri GL-104 bacterial strain M209138 to the enhancement effect of Th1 type immunological competence, it is the secretory volume of measuring cell interleukin 12 p40 (IL-12p40) after mensuration human dcs (dendritic cell) and the aforementioned antianaphylaxis milk-acid bacteria co-cultivation, verifies the bacterial strain with antianaphylaxis ability.Use following experimental procedure:
1. extract at every turn about 200mL of suitable human blood amount.
2. the blood cell parting liquid (Ficoll-paque) of getting equal proportion with blood at 18-20 ℃ with the centrifugal 30-40 of 400g minute.
3. get human peripheral blood mononuclearcell (PBMC) layer, after buffered soln cleans cell 2-3 time, with suitable substratum (for example RPMI-1640) suspension cell.
4. human peripheral blood mononuclearcell (PBMC) cell is with CD14
+Microbeads (MiniMACSsystem) is with the CD14 of cell
+The monocyte purifying.
5. be divided into dendritic cell with cytohormone (IL-4) and tethelin (GM-CSF) irritation cell, 6-7 days incubation time is collected the dendritic cell of having broken up.
6. with the activation in 3 days before co-cultivation of antianaphylaxis lactic bacterium strains, afterwards with 100 ℃ of dead lactic bacterium strains of thermic 30 minutes.
7. the lactobacillus strain that dendritic cell and thermic is dead was with 1: 10 ratio co-cultivation 48 hours.
8. collect the supernatant liquor of cell cultures.Utilize the content of enzyme-linked immunosorbent assay (ELISA) detecting cell interleukin 12 p40 (IL-12p40) in supernatant liquor.
The statistical study of data such as table 5 and shown in Figure 3 represent with Mean ± SD.Figure 3 shows that ought be respectively with thermic dead 10
6To 10
8Cfu lactobacillus reuteri GL-104 bacterial strain M 209138 and 10
5To 10
7Individual human dcs co-cultivation 48 hours is collected cell conditioned medium liquid, with the content of enzyme-linked immunosorbent assay detecting cell interleukin 12 p40 (IL-12p40) in supernatant liquor.Wherein take without antianaphylaxis function milk-acid bacteria (Lactobacillus casei BCRC 17001) and Experimental Background value (Cell only) as negative control group, prove its milk-acid bacteria that antianaphylaxis effect is arranged (Lactobacillus rhamnosus GG BCRC16000) and LPS (Lipopolysaccharide) as the positive control group to deliver most literature, detecting cell interleukin 12 p40 (IL-12p40) irriate concentration.The result show test group significantly stimulating human dendritic cell secretory cell interleukin 12 p40 (IL-12p40) and negative control group (Lactobacillus casei BCRC 17001) significant difference is arranged, and exceed 2 times than the quantity of stimulus of positive control group (Lactobacillus rhamnosus GG BCRC 16000).Table 5 is depicted as respectively with the dead antianaphylaxis lactic bacterium strains of thermic and control group and dendritic cell and cultivates, the secretory volume of irritation cell interleukin 12 p40 (IL-12p40) (means ± SD):
Table 5
| Strain name | The secretory volume (pg/mL) of cell interleukin 12 p40 |
| Positive control group (L.rhamnosus GG BCRC 16000) | 6905±611 |
| Lactobacillus reuteri GL-104M 209138 | 14425±1741 |
| Negative control group (L.casei BCRC17001) | 51±2 |
| Positive control group (LPS) | 22103±780 |
| Negative control group (Cell only) | 20±147 |
Embodiment 4: the stomach juice-resistant cholate test of antianaphylaxis milk-acid bacteria.
Whether inspect antianaphylaxis lactobacillus strain of the present invention-lactobacillus reuteri GL-104 bacterial strain M 209138 and have by the ability of hydrochloric acid in gastric juice cholate test and bring into play its antianaphylactic function at enteron aisle smoothly, experiment process is as follows:
1. with antianaphylaxis milk-acid bacteria activation of the present invention 3 days.
2. get 1mL bacterium liquid and calculate original bacterium number, remaining milk-acid bacteria centrifugal 10 minutes with 500g adds the washed with de-ionized water milk-acid bacteria 2-3 time.
3. add and be deployed in the substratum of pH 2.5 with hydrochloric acid, antianaphylaxis milk-acid bacteria of the present invention places 37 ℃ of incubators with after the substratum of pH 2.5 fully mixes.
4. the bacterium liquid that per hour takes out 1mL with washed with de-ionized water 2-3 time after, the calculating survivaling cell number is till 3 hours incubation times.
5. residue bacterium liquid centrifuged deposit thing is again with Hui Rong in the substratum that contains 1.5% (w/V) oxgall (ox gall, Sigma), after fully mixing, in 37 ℃ of cultivations.
6. the bacterium liquid that per hour takes out 1mL with washed with de-ionized water 2-3 time after, the calculating survivaling cell number is till 4 hours incubation times.
7. record lactobacter growth speed is calculated milk-acid bacteria to the tolerance of hydrochloric acid in gastric juice and cholate, and so that antianaphylaxis milk-acid bacteria of the present invention is in the presence of hydrochloric acid in gastric juice and cholate in the comparative sample, whether strain growth is suppressed.
The capability result of stomach juice-resistant and analysis and arrangement are in table 6 and shown in Figure 4, result shown in Figure 4 shows, antianaphylaxis milk-acid bacteria of the present invention is after the substratum activation, bacterial strain is processed acidic buffer solution and cholate, lactobacillus reuteri GL-104 bacterial strain M 209138 bacterium numbers are not subjected to the impact of hydrochloric acid in gastric juice and cholate and sharply descend, and prove that antianaphylaxis milk-acid bacteria of the present invention can be by the test of the strict environment of digestion.Table 6 is that the hydrochloric acid with pH value 2.5 mixes test its stomach juice-resistant ability (Logmeans ± Log SD) with antianaphylaxis milk-acid bacteria of the present invention:
Table 6
| Strain name | Original bacterium number (Log cfu/mL) | pH2.5-1hr (Log cfu/mL) | pH2.5-2hr (Log cfu/mL) | pH2.5-3hr (Log cfu/mL) |
| Lactobacillus reuteri M 209138 | 9.33±0.012 | 9.15±0.15 | 8.92±0.28 | 8.49±0.14 |
The capability result of bile tolerance and analysis and arrangement are in table 7 and shown in Figure 4, and table 7 is that the bile (bile) with 1.5% mixes test its bile tolerance ability (Log means ± Log SD) with antianaphylaxis milk-acid bacteria of the present invention:
Table 7
| Strain name | Original bacterium number (Log cfu/mL) | 1.5％bile -1hr (Log | 1.5％bile -2hr (Log | 1.5％bile -3hr (Log | 1.5％bile -4hr (Log |
[0068]
| cfu/mL) | cfu/mL) | cfu/mL) | cfu/mL) | ||
| Lactobacillus reuteri M 209138 | 9.33±0.012 | 8.22±0.39 | 8.03±0.026 | 8.11±0.091 | 7.96±0.15 |
Embodiment 5: the antianaphylaxis milk-acid bacteria is to the adsorptive power test of human intestine's epidermic cell (Caco-2).
Adopt the cell strain that has broken up to analyze the ability of antianaphylaxis lactic bacterium strains absorption human intestine's epidermic cell of the present invention (Caco-2) in vitro.Elder generation, is inserted in the porous cell culture plate after growing to monolayer cell on the cover glass by the strain of human intestine's epidermic cell (Caco-2) monolayer cell.Then with cell: the ratio of milk-acid bacteria is 1: 200, co-cultivation 1-3 hour, with buffered soln clean and utilize the methyl alcohol fixed cell and remaining adhere to the bacterium number after, carry out gramstaining and determine accompanying bacterium number.With reference to the analytical procedure of the scholars such as Jacobsen (1999), 20 visuals field of counting when the average bacterium number in each visual field is less than 40, are judged to be non-cohesive (nonadhesive) under 1000 power microscopes; When the average bacterium number in each visual field between 41 to 100 the time, be judged to be and adhere to (adhesive); When the average bacterium number in each visual field greater than 100 the time, be judged to be strong adhesion (strongly adhesive).
The statistical study of data represents with Mean ± SD.On average, get the calculated value in 45 visuals field, its result puts in order in table 8 and Fig. 5.Fig. 5 shows that lactobacillus reuteri GL-104 bacterial strain M 209138 is judged to be " strong adhesion ".Table 8 is that antianaphylaxis milk-acid bacteria of the present invention is to the adsorptive power test of human intestine's epidermic cell (Caco-2) cell strain.
Table 8
| Strain name | Means±SD |
| Lactobacillus reuteri M 209138 | 204±58 |
Because milk-acid bacteria will be brought into play antianaphylactic effect except will finding out the bacterial strain with specific function, to confirm that more this bacterial strain can be by outside the environment of human body hydrochloric acid in gastric juice cholate, the lactic bacterium strains that also will can have to the small intestinal mucosa epidermic cell favourable absorption ability, also because of this specific character, antianaphylaxis milk-acid bacteria of the present invention just can provide the medical use for the treatment of or the allergic symptom of releiving.Antianaphylaxis milk-acid bacteria described in the invention can strengthen the anaphylaxis that Th1 approach regulation and control Th2 crosses Sheng simultaneously.A target of the present invention be exactly continue towards reach these demands or provide at least popular in the allergy treatment except steroid or antihistaminic new selection, the present invention finds out human body is had no side effect and wholesome antianaphylaxis milk-acid bacteria is used as the new selection of irritated treatment.
Above-described embodiment only is for technological thought of the present invention and characteristics are described, its purpose is to make those skilled in the art can understand content of the present invention and implements according to this, when can not with restriction claim of the present invention, the equalization of namely generally doing according to disclosed spirit changes or modifies, and must be encompassed in the claim of the present invention.
Claims (6)
1. food compositions comprises:
The lactic bacterium strains of immune stimulatory emiocytosis antianaphylaxis relevant cell hormone: lactobacillus reuteri (Lactobacillus reuteri) GL-104 bacterial strain, Chinese Typical Representative culture collection center preserving number M 209138; And
Physiologically acceptable vehicle.
2. food compositions as claimed in claim 1, wherein this vehicle is a kind of food.
3. food compositions as claimed in claim 2, wherein this food comprises fermented-milk, cheese, milk powder, tea, coffee or above combination.
4. food compositions as claimed in claim 1, wherein this lactic bacterium strains is for having the bacterial strain of activity or deactivation (inactivated).
5. one kind is used for the treatment of irritated medical composition, comprises:
The lactic bacterium strains of immune stimulatory emiocytosis antianaphylaxis relevant cell hormone: lactobacillus reuteri (Lactobacillus reuteri) GL-104 bacterial strain, Chinese Typical Representative culture collection center preserving number M 209138; And
Pharmaceutically acceptable vehicle.
6. medical composition as claimed in claim 5, wherein this lactic bacterium strains is for having the bacterial strain of activity or deactivation (inactivated).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102267377A CN102309001B (en) | 2010-07-01 | 2010-07-01 | Food composition and pharmaceutical composition of lactic acid bacteria strains for treating allergies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102267377A CN102309001B (en) | 2010-07-01 | 2010-07-01 | Food composition and pharmaceutical composition of lactic acid bacteria strains for treating allergies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102309001A CN102309001A (en) | 2012-01-11 |
| CN102309001B true CN102309001B (en) | 2013-04-03 |
Family
ID=45422869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102267377A Active CN102309001B (en) | 2010-07-01 | 2010-07-01 | Food composition and pharmaceutical composition of lactic acid bacteria strains for treating allergies |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102309001B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9587284B2 (en) * | 2014-02-21 | 2017-03-07 | Asian Probiotics and Prebiotics Ltd. | Lactic acid bacterium having immunomodulatory and anti-allergic effects and pharmaceutical composition containing the same |
| CN107050063A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of allergic constitution and preparation method thereof |
| CN108338305A (en) * | 2017-01-22 | 2018-07-31 | 上海法太实业有限公司 | A kind of compound powder solid beverage of probiotics |
| TWI639389B (en) * | 2017-01-24 | 2018-11-01 | 豐華生物科技股份有限公司 | Food, oral cleaning and pharmaceutical composition with strains of lactic acid bacteria for inhibiting of oral pathogens |
| CN107114794A (en) * | 2017-06-06 | 2017-09-01 | 上海真合生物技术有限公司 | Probiotic composition for strengthening antiallergy ability |
| TWI709374B (en) * | 2019-06-14 | 2020-11-11 | 豐華生物科技股份有限公司 | Use of food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328468A (en) * | 2007-06-21 | 2008-12-24 | 东宇生物科技股份有限公司 | Antiallergic lactic acid bacteria |
| CN101575582A (en) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | Lactobacillus isolate with anti-inflammatory activity and use thereof |
-
2010
- 2010-07-01 CN CN2010102267377A patent/CN102309001B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328468A (en) * | 2007-06-21 | 2008-12-24 | 东宇生物科技股份有限公司 | Antiallergic lactic acid bacteria |
| CN101575582A (en) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | Lactobacillus isolate with anti-inflammatory activity and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| John I.B.Alak,et al..Effect of Lactobacillus reuteri on Intestinal Resistance to Cryptosporidium parvum Infection in a Murine Model of Acquired Immunodeficiency Syndrome.《The Journal of Infectious Diseases》.1997,第175卷(第1期),218-221. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309001A (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114317320B (en) | Bifidobacterium breve 207-1 and application thereof | |
| US9011839B2 (en) | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing Lactobacillus | |
| CN102309001B (en) | Food composition and pharmaceutical composition of lactic acid bacteria strains for treating allergies | |
| AU2007231917B2 (en) | Anti-Allergy Lactic Acid Bacteria | |
| CN102835657B (en) | Lactic acid bacteria-containing food composition and pharmaceutical composition for inhibiting inflammatory response and anti-vaginitis | |
| CN110106119B (en) | Lactobacillus rhamnosus M9 separated from breast milk and application thereof | |
| CN102399718B (en) | Lactobacillus paracasei strain GMNL‑133, compositions for improving atopic dermatitis or other allergic diseases and uses thereof | |
| CN104480032A (en) | Lactobacillus plantarum boosting immunological competence | |
| CN113088463A (en) | Lactobacillus acidophilus with probiotic characteristics and application thereof | |
| Matsumoto et al. | Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512 | |
| KR20120125359A (en) | Anti-allergic composition | |
| WO2011076007A1 (en) | Lactobacillus paracaseistrain lt12 as anti-allergy agent | |
| CN116676225B (en) | Lactobacillus rhamnosus LR-28 strain with nerve soothing and sleep aiding effects, fermentation product, hypnotic fungus group mixture and application | |
| CN101328468A (en) | Antiallergic lactic acid bacteria | |
| CN106222158A (en) | A kind of microcapsule preparation method embedding lactobacillus | |
| CN107114794A (en) | Probiotic composition for strengthening antiallergy ability | |
| TWI398259B (en) | Composition and use of lactobacillus paracasei strain gmnl-133 in treating atopic dermatitis or other allergic diseases | |
| CN101503662B (en) | Microbial strains for anti-allergic symptoms, composition thereof and method for stimulating cells to produce interferon-γ with the microbial strains | |
| CN102899261B (en) | Application of Bifidobacterium longum subspecies longum BR022 strain | |
| Hati et al. | Safety aspects, probiotic potentials of yeast and lactobacillus isolated from fermented foods in North-Eastern India, and its anti-inflammatory activity | |
| CN1329505C (en) | Lactobacillus fermentum GM-090 and its use in the production of drugs that stimulate INF-γ secretion and/or treat allergies | |
| CN113908176B (en) | Composition for preventing and treating food allergy | |
| US20110052553A1 (en) | Strain of lactobacillus plantarum lp28 and its use in treating hypersensitivity reactions | |
| CN102657260B (en) | Anti-allergic lactic acid bacteria | |
| KR100865363B1 (en) | Bifidobacterium inpantis MAIEL-B Bifidus lactic acid bacteria and health functional food containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221010 Address after: No. 2, Jingyi Road, Huai'an Economic and Technological Development Zone, Jiangsu Province Patentee after: JINQIAO BIOTECHNOLOGY CO.,LTD. Address before: 2, 3, 17, international road, Xinshi County, Tainan, Taiwan, China Patentee before: GLAC BIOTECH Co.,Ltd. |